PMID- 17198090
OWN - NLM
STAT- MEDLINE
DCOM- 20070302
LR  - 20201212
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 30
IP  - 1
DP  - 2007 Jan
TI  - Preliminary analysis of patients with progressive renal cell carcinoma vaccinated 
      with CA9-peptide-pulsed mature dendritic cells.
PG  - 116-22
AB  - Carbonic anhydrase-IXG250/MN (CA9) is a renal cell carcinoma (RCC)-associated 
      antigen ubiquitously expressed in the clear-cell subtype of RCC. Two CA9-derived 
      peptides have been identified defining a cytotoxic T-lymphocyte epitope and human 
      leukocyte antigen (HLA)-DR epitope, able to induce T-cell responses in vitro. A 
      phase I clinical trial was performed with CA9-peptide-loaded dendritic cells 
      (DCs) in patients with progressive, cytokine-refractory metastatic RCC to assess 
      the safety, toxicity, and induction of CA9-specific immunity. Patients with 
      objective progressive metastatic RCC received 5 vaccinations of mature DCs pulsed 
      with the CA9-derived peptides and keyhole limpet hemocyanine (KLH). Peripheral 
      blood was collected at regular intervals, delayed-type hypersensitivity (DTH) was 
      tested at baseline and after the last vaccination, and skin biopsies of positive 
      DTH sites were collected for immunomonitoring purposes. Patients were also 
      monitored for clinical responses. No significant toxicity was observed. All 
      patients developed humoral responses against KLH, and demonstrated DTH 
      conversion. Evaluation of biopsy material suggested an increased influx of 
      T-helper cells. In none of the immunomonitoring assays was evidence for the 
      induction of CA9-peptide-specific immunity observed. No clinical responses were 
      observed. The vaccination of DCs pulsed with KLH and 2 CA9-derived peptides was 
      well tolerated. The lack of induction of CA9-peptide-specific immune responses 
      indicates that this particular vaccine regimen is poor in inducing 
      CA9-peptide-specific immune responses.
FAU - Bleumer, Ivar
AU  - Bleumer I
AD  - University Medical Center, Nijmegen, The Netherlands.
FAU - Tiemessen, Dorien M
AU  - Tiemessen DM
FAU - Oosterwijk-Wakka, Jeannette C
AU  - Oosterwijk-Wakka JC
FAU - Voller, Maureen C W
AU  - Voller MC
FAU - De Weijer, Kim
AU  - De Weijer K
FAU - Mulders, Peter F A
AU  - Mulders PF
FAU - Oosterwijk, Egbert
AU  - Oosterwijk E
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antigens, Neoplasm)
RN  - EC 4.2.1.1 (CA9 protein, human)
RN  - EC 4.2.1.1 (Carbonic Anhydrase IX)
RN  - EC 4.2.1.1 (Carbonic Anhydrases)
SB  - IM
MH  - Amino Acid Sequence
MH  - Antibody Formation/immunology
MH  - Antigens, Neoplasm/*immunology
MH  - Carbonic Anhydrase IX
MH  - Carbonic Anhydrases/*immunology
MH  - Carcinoma, Renal Cell/blood/immunology/*therapy
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Hypersensitivity, Delayed/blood/immunology
MH  - Immunity, Cellular/immunology
MH  - Immunotherapy, Adoptive/adverse effects/*methods
MH  - Kidney Neoplasms/blood/immunology/*therapy
MH  - Molecular Sequence Data
EDAT- 2007/01/02 09:00
MHDA- 2007/03/03 09:00
CRDT- 2007/01/02 09:00
PHST- 2007/01/02 09:00 [pubmed]
PHST- 2007/03/03 09:00 [medline]
PHST- 2007/01/02 09:00 [entrez]
AID - 00002371-200701000-00012 [pii]
AID - 10.1097/01.cji.0000211318.22902.ec [doi]
PST - ppublish
SO  - J Immunother. 2007 Jan;30(1):116-22. doi: 10.1097/01.cji.0000211318.22902.ec.